UPDATE 1-FDA panel: BioMarin DMD drug data not persuasive enough

Nov 24 (Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration indicated that efficacy data from BioMarin Pharmaceutical Inc on its experimental drug for treating a muscle wastage disorder was not persuasive enough.